InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: None

Friday, 03/17/2017 3:56:10 PM

Friday, March 17, 2017 3:56:10 PM

Post# of 18784
"According to ASCO in 2015, best option for EC 2nd line treatment was… enrolling in the ZoptEC trial, no joke!"
http://ascopubs.org/doi/full/10.1200/JCO.2015.61.7225

Great Post from maggie_on_rails on stocktwits
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AEZS News